CREB expression mediates amyloid β-induced basal BDNF downregulation

Neurobiology of Aging

Volumn 36, Issue 8, 2015, Pages 2406-2413

  Rosa, Elyse ^a   Fahnestock, Margaret ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Amyloid ; Brain derived neurotrophic factor; CAMP response element binding protein; Human neuroblastoma SH SY5Y; MRNA

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; AMYLOID BETA PROTEIN; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; CREBBP PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN;

ARTICLE; CELL STIMULATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SH SY5Y CELL LINE; TRANSCRIPTION REGULATION; ALZHEIMER DISEASE; BASAL GANGLION; CELL NUCLEUS; CYTOPLASM; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BASAL GANGLIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TUMOR; CELL NUCLEUS; CREB-BINDING PROTEIN; CYTOPLASM; DOWN-REGULATION; HUMANS; PHOSPHORYLATION; TRANSCRIPTION, GENETIC;

EID: 84952638033     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.04.014     Document Type: Article

References (54)

1. Allen S.J., Watson J.J., Dawbarn D. The neurotrophins and their role in Alzheimer's disease. Curr. Neuropharmacol. 2011, 9:559-573.
2. Ando S., Kobayashi S., Waki H., Kon K., Fukui F., Tadenuma T., Iwamoto M., Takeda Y., Izumiyama N., Watanabe K., Nakamura H. Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. J. Neurosci. Res. 2002, 70:519-527.
3. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
4. Barco A., Pittenger C., Kandel E.R. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin. Ther. Targets 2003, 7:101-114.
5. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13594-13599.
6. Caccamo A., Maldonado M.A., Bokov A.F., Majumder S., Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:22687-22692.
7. Choi Y.J., Kim S.I., Lee J.W., Kwon Y.S., Lee H.J., Kim S.S., Chun W. Suppression of aggregate formation of mutant huntingtin potentiates CREB-binding protein sequestration and apoptotic cell death. Mol. Cell Neurosci. 2012, 49:127-137.
8. Coleman P.D., Flood D.G. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol. Aging 1987, 8:521-545.
9. Coleman P.D., Yao P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging 2003, 24:1023-1027.
10. Connor B., Young D., Yan Q., Faull R.L., Synek B., Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res. 1997, 49:71-81.
11. DaRocha-Souto B., Coma M., Perez-Nievas B.G., Scotton T.C., Siao M., Sanchez-Ferrer P., Hashimoto T., Fan Z., Hudry E., Barroeta I., Sereno L., Rodriguez M., Sanchez M.B., Hyman B.T., Gomez-Isla T. Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol. Dis. 2012, 45:425-437.
12. Encinas M., Iglesias M., Liu Y., Wang H., Muhaisen A., Cena V., Gallego C., Comella J.X. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 2000, 75:991-1003.
13. Espana J., Valero J., Minano-Molina A.J., Masgrau R., Martin E., Guardia-Laguarta C., Lleo A., Gimenez-Llort L., Rodriguez-Alvarez J., Saura C.A. beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J. Neurosci. 2010, 30:9402-9410.
14. Fahnestock M. Brain-derived neurotrophic factor: the link between amyloid-β and memory loss. Future Neurol. 2011, 6:627-639.
15. Fahnestock M., Marchese M., Head E., Pop V., Michalski B., Milgram W.N., Cotman C.W. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol. Aging 2012, 33:546-554.
16. Feng X., Jiang H., Baik J.C., Edgar C., Eide F.F. BDNF dependence in neuroblastoma. J. Neurosci. Res. 2001, 64:355-363.
17. Ferreira S.T., Vieira M.N., De Felice F.G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 2007, 59:332-345.
18. Ferrer I., Marin C., Rey M.J., Ribalta T., Goutan E., Blanco R., Tolosa E., Marti E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 1999, 58:729-739.
19. Francis B.M., Kim J., Barakat M.E., Fraenkl S., Yucel Y.H., Peng S., Michalski B., Fahnestock M., McLaurin J., Mount H.T. Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. Neurobiol. Aging 2012, 33:555-563.
20. Garzon D., Yu G., Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J. Neurochem. 2002, 82:1058-1064.
21. Garzon D.J., Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 2007, 27:2628-2635.
22. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J. Mol. Neurosci. 2001, 17:137-145.
23. Grimes C.A., Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem. 2001, 78:1219-1232.
24. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
25. Hock C., Heese K., Hulette C., Rosenberg C., Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000, 57:846-851.
26. Holsinger R.M., Schnarr J., Henry P., Castelo V.T., Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res. 2000, 76:347-354.
27. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.S., Nelson P.T., Schneider J.A., Thal D.R., Thies B., Trojanowski J.Q., Vinters H.V., Montine T.J. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012, 8:1-13.
28. Hyman B.T., Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:1095-1097.
29. Kaplan D.R., Matsumoto K., Lucarelli E., Thiele C.J. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. Neuron 1993, 11:321-331.
30. Ke Y.D., Dramiga J., Schutz U., Kril J.J., Ittner L.M., Schroder H., Gotz J. Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. PLoS One 2012, 7:e35678.
31. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27:796-807.
32. Lambert M.P., Stevens G., Sabo S., Barber K., Wang G., Wade W., Krafft G., Snyder S., Holzman T.F., Klein W.L. Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. J. Neurosci. Res. 1994, 39:377-385.
33. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem. 2003, 10:86-98.
34. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
35. Michalski B., Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 111:148-154.
36. Nagahara A.H., Mateling M., Kovacs I., Wang L., Eggert S., Rockenstein E., Koo E.H., Masliah E., Tuszynski M.H. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J. Neurosci. 2013, 33:15596-15602.
37. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 2009, 15:331-337.
38. Peng S., Garzon D.J., Marchese M., Klein W., Ginsberg S.D., Francis B.M., Mount H.T., Mufson E.J., Salehi A., Fahnestock M. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J. Neurosci. 2009, 29:9321-9329.
39. Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 2005, 93:1412-1421.
40. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991, 7:695-702.
41. Pruunsild P., Kazantseva A., Aid T., Palm K., Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007, 90:397-406.
42. Pruunsild P., Sepp M., Orav E., Koppel I., Timmusk T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J. Neurosci. 2011, 31:3295-3308.
43. Pugazhenthi S., Wang M., Pham S., Sze C.I., Eckman C.B. Downregulation of CREB expression in Alzheimer's brain and in Abeta-treated rat hippocampal neurons. Mol. Neurodegener. 2011, 6:60.
44. Rosa E., Cha J., Bain JR., Fahnestock M. Calcitonin gene-related peptide regulation of glial cell-line derived neurotrophic factor in differentiated rat myotubes. J. Neurosci. Res. 2015, 93:514-520.
45. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 2003, 24:1029-1046.
46. Seamon K.B., Daly J.W. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J. Cyclic Nucleotide Res. 1981, 7:201-224.
47. Shieh P.B., Hu S.C., Bobb K., Timmusk T., Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 1998, 20:727-740.
48. Tao X., Finkbeiner S., Arnold D.B., Shaywitz A.J., Greenberg M.E. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998, 20:709-726.
49. Tong L., Balazs R., Thornton P.L., Cotman C.W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 2004, 24:6799-6809.
50. Tong L., Thornton P.L., Balazs R., Cotman C.W. Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J. Biol. Chem. 2001, 276:17301-17306.
51. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13217-13221.
52. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
53. Walton M.R., Dragunow I. Is CREB a key to neuronal survival?. Trends Neurosci. 2000, 23:48-53.
54. Wang Q.M., Roach P.J., Fiol C.J. Use of a synthetic peptide as a selective substrate for glycogen synthase kinase 3. Anal. Biochem. 1994, 220:397-402.